Initiation of Coverage Integra LifeSciences Holdings Corp: Cleaning Up. Neutral at $19 PT.

研报英文原文证据摘录

Initiation of Coverage Integra LifeSciences Holdings Corp: Cleaning Up. Neutral at $19 PT.

ould help to

bolster performance, in our minds; and, with peak ship-hold disruption behind it, IART's compliance

foundation is materially firmer than it was a year ago, which removes a key source of downside

variance. On the balance sheet, we think the heaviest cash outflows (namely the 2025 inventory

build) are entering a period of normalization, and a debt stack that skews fixed (via hedges) makes

the forward FCF and deleveraging path more predictable. This said, we're in "wait-and-see mode."

EVIDENCE IART’s outlook is supported by leading positions in structurally MSD-growth end markets and

sustained R&D investment (~5.3% of sales over the last five years). The company is also operating

from a much stronger foundation than a year ago, having progressed through its CMP ahead of

schedule, resumed production at Braintree earlier than expected, and avoided any new ship holds

through 1Q26. With Street expectations remaining conservative (~0.5% organic growth in 2Q26),

we think the projected acceleration into FY27-FY28 is reasonable. Meanwhile, inventory-related cash

headwinds are easing, supporting FCF recovery, while IART’s largely fixed-rate debt profile limits

interest-rate sensitivity and should facilitate continued deleveraging.

WHAT´S PRICED IN? Our reverse DCF implies the market is pricing in ~3% sales CAGR from 2025 through 2030, which is

in line with us at approx. 3%. At today's price, shares roughly reflect what we view as reasonable

growth, and we see few near-term catalysts to drive the stock up or down.Please

Upside/Downside

Spectrum

Valuedrivers EV / Sales Multiple Upside / Downside Revenue Skew

$24 upside ~1.9x +2%

$19 base ~1.7x -

$14 downside ~1.5x -2%